Raffaele Colombo, Associate Director, Medicinal Chemistry at Zymeworks Inc., shared on X about a recent paper by Tongtong Xue et al. published in AACR Journals:
“IND approved by Chinese NMPA for YL242, a non-internalizing ADC targeting soluble VEGF, with a TOPO1i payload, and DAR=4.
They recently presented a poster on its preclinical development at AACR25 in Chicago.”
Title: Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
Authors: Tongtong Xue, Wei Lian, Qing Zong, Chun Deng, Qigang Liu, Peng Zou, Jiaqiang Cai
More posts featuring Raffaele Colombo.